Dose escalation study of the HLA-A2-WT1 CD3 bispecific antibody RO7283420 in relapsed/refractory acute myeloid leukemia Blood Neoplasia
Corrigendum to "Opposing effects of the purinergic P2X7 receptor on seizures in neurons and microglia in male mice" [Brain Behav. Immun. 120 (2024) 121-140] Brain Behav Immun
HDAC7 induction combined with standard-of-care chemotherapy provides a therapeutic advantage in t(4;11) infant B-cell acute lymphoblastic leukemia Biomark Res
Long-term results from the AGILE study of azacitidine plus ivosidenib vs placebo in newly diagnosed IDH1-mutated AML Blood Adv
Proteins of the cancer cell secretome induce the protumoral microenvironment of diffuse intrinsic pontine glioma NEURO-ONCOL ADV
Prognostic impact of cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with risk-adapted protocols MED CLIN-BARCELONA
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial Lancet Oncol